Autologous CD133+ hematopoietic stem cells (University of Wisconsin-Madison)

N/A

Report date: 2023/01/12 15:51:53

Base Information

Drug NameAutologous CD133+ hematopoietic stem cells (University of Wisconsin-Madison)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionAnti-CD133
TargetsCD133
Therapy Area/IndicationsPeripheral Arterial Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Wisconsin-Madison
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Wisconsin-Madison
Active IndicationsN/A
Inactive IndicationsPeripheral Arterial Disease

Other Information

ATC CodeN/A
Related LinksN/A